The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Catalyst Pharmaceutical Partners, Inc. -- CPRX
GlobeNewswire - Thu Dec 18, 7:10AM CST
The Rosen Law Firm, P.A. announces that the United States District Court Southern District of Florida has approved the following announcement of a proposed class action settlement that would benefit purchasers of common stock of Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX):
CPRX: 2.90 (-0.02)
Catalyst Pharma founder passes
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 8:54AM CST
CPRX: 2.90 (-0.02)
Catalyst Pharmaceuticals expresses sympathy on passing of co-founder and director Dr Hubert E. Huckel
M2 - Wed Dec 17, 7:59AM CST
Biopharmaceutical company Catalyst Pharmaceutical Partners (NasdaqCM:CPRX) reported on Tuesday that its co-founder and director Dr Hubert E. Huckel, MD has died.
CPRX: 2.90 (-0.02)
Catalyst Pharmaceuticals Announces the Passing of Hubert E. Huckel, Co-Founder and Director
GlobeNewswire - Tue Dec 16, 2:45PM CST
Catalyst Pharmaceutical Partners, Inc. (Catalyst Pharmaceuticals) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced with great sadness the loss of Co-Founder and director, Hubert E. Huckel, M.D. Dr. Huckel, a founding shareholder and director of Catalyst since its formation in January 2002, passed away on December 13, 2014.
CPRX: 2.90 (-0.02)
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014
M2 - Thu Dec 11, 3:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/srj257/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Addex Therapeutics - Azevan Pharmaceuticals - Catalyst Pharmaceutical Partners - Humanetics Corporation - Intra-Cellular Therapies - Marinus Pharmaceuticals - Nanotherapeutics - Neuralstem - Neurocrine Biosciences - NeuroNascent - Omeros Corporation - Otsuka Holdings - Pfizer - Polleo Pharma - Tonix Pharmaceuticals Holding - Vanda Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/sr...ttraumatic
NBIX: 21.33 (+0.09), TNXP: 6.18 (-0.09), MRNS: 8.75 (+0.54), CPRX: 2.90 (-0.02), VNDA: 14.69 (+1.11), ITCI: 17.99 (+0.16), OMER: 22.09 (+0.48)
Catalyst Pharmaceuticals to Present at the Piper Jaffray 26th Annual Healthcare Conference
GlobeNewswire - Mon Dec 01, 7:03AM CST
Catalyst Pharmaceutical Partners, Inc. (Catalyst Pharmaceuticals) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that Patrick J. McEnany, Chief Executive Officer, and Steven Miller, Ph.D., Chief Operating Officer and Chief Scientific Officer, will present at the Piper Jaffray 26 Annual Healthcare Conference held at The New York Palace Hotel in New York City, Dec. 2-3. The presentation is scheduled for Tuesday, Dec. 2 at 12:00 p.m. EST. The presentation materials will be posted at www.catalystpharma.com in the Investors section under Events & Presentations.
CPRX: 2.90 (-0.02)
Catalyst Pharmaceuticals receives US patent's Notice of Allowance for protecting CPP-115 for neurological and psychological uses
M2 - Tue Nov 25, 8:29AM CST
Biopharmaceutical company Catalyst Pharmaceutical Partners (NasdaqCM:CPRX) disclosed on Monday the receipt of the US Patent and Trademark Office's (USPTO) Notice of Allowance for covering its drug candidate CPP-115 for neurological and psychological uses.
CPRX: 2.90 (-0.02)
Catalyst Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application for the Reduction or Elimination of Visual Field Defects by Treating Patients With CPP-115
GlobeNewswire - Mon Nov 24, 7:03AM CST
Catalyst Pharmaceutical Partners, Inc. (Catalyst Pharmaceuticals) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 13/581,187. The patent application is generally directed to methods reducing visual field defects and intramyelinic edema resulting from the use of a GABA-aminotransferase inhibitor by using CPP-115, a new and novel GABA-AT inactivator, to treat neurological or psychological disorders.
CPRX: 2.90 (-0.02)
Catalyst Pharma net loss improves in Q3
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 8:47AM CST
CPRX: 2.90 (-0.02)
Catalyst Pharmaceutical misses by $0.01
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 7:21AM CST
CPRX: 2.90 (-0.02)
Catalyst Pharmaceuticals Announces Third Quarter 2014 Financial Results
GlobeNewswire - Fri Nov 14, 7:03AM CST
Catalyst Pharmaceutical Partners, Inc. (Catalyst Pharmaceuticals) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported financial results for the third quarter and nine months ended September 30, 2014.
CPRX: 2.90 (-0.02)
Will Catalyst Pharmaceuticals' (CPRX) Loss Narrow in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:30PM CST
Catalyst Pharmaceuticals Inc, Inc. (CPRX) is expected to report third-quarter 2014 results on Nov 13.
MNK: 97.84 (-0.29), BMRN: 88.18 (+0.89), CPRX: 2.90 (-0.02)
Catalyst Pharmaceuticals Announces Proposed Settlement of Pending Securities Class Action Lawsuit
GlobeNewswire - Tue Nov 04, 7:03AM CST
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) (Catalyst Pharmaceuticals or the Company), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that it has entered into a memorandum of understanding ("MOU"
CPRX: 2.90 (-0.02)
i"Catalyst Pharmaceuticals elects David J. Caponera as VP of patient advocacy and reimbursement
M2 - Wed Oct 29, 5:05AM CDT
Biopharmaceutical company Catalyst Pharmaceutical Partners (NasdaqCM:CPRX) revealed on Tuesday the election of David J. Caponera to the newly created position of vice president, patient advocacy and reimbursement.
CPRX: 2.90 (-0.02)
Catalyst Pharmaceuticals Appoints David J. Caponera as Vice President Patient Advocacy and Reimbursement
GlobeNewswire - Tue Oct 28, 7:03AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, announced the appointment of David J. Caponera to the newly created position, vice president, patient advocacy and reimbursement, effective immediately. Mr. Caponera will report to David D. Muth, executive vice president, corporate development.
CPRX: 2.90 (-0.02)
Catalyst Pharmaceuticals to Present Firdapse Phase 3 Trial Results at the 61st Annual Meeting of the American Association of Neuromuscular and Electrodiagnostic Medicine
GlobeNewswire - Mon Oct 27, 7:03AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that safety and efficacy results from its Firdapse(TM) Phase 3 trial will be presented as part of an Industry Forum at the 61 Annual Meeting of the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) being held at the Savannah, Georgia International Trade and Convention Center, Oct. 29-Nov. 1. The Catalyst-sponsored forum will occur on Friday, Oct, 31 at 12:00 pm EDT and include presentations on the diagnosis and treatment of LEMS and Congenital Myasthenic Syndrome (CMS) by several Firdapse Phase 3 clinical study investigators and the Firdapse Expanded Access Program (EAP) by Catalyst's chief medical officer. Catalyst will also be exhibiting at booth #515 during the AANEM. The presentation materials will be posted at www.catalystpharma.com in the Investors section under Events & Presentations.
CPRX: 2.90 (-0.02)
Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners
PR Newswire - Fri Oct 17, 8:30AM CDT
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), XOMA Corporation (NASDAQ: XOMA), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), and Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, October 16, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 16,117.24, down 0.15% and the NASDAQ Composite closed at 4,217.39, up 0.05%. The S&P 500 finished the session 0.01% higher at 1,862.76. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 696.64, down 0.50%, whereas the index has advanced 8.46% on YTD basis. Register for your complimentary reports on these five stocks at:
CPRX: 2.90 (-0.02), NPSP: 35.06 (+1.18), MNTA: 11.42 (-0.06), ARNA: 3.57 (-0.01), XOMA: 3.68 (+0.11)
Catalyst Pharmaceuticals to Present Top-Line Safety and Efficacy Results From Phase 3 Firdapse Trial at 139th Annual Meeting of the American Neurological Association
GlobeNewswire - Wed Oct 08, 7:35AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals) a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that Douglas Winship, Vice President of Regulatory Operations, will present top-line safety and efficacy results from Catalyst's Phase 3 Firdapsetrial at the 139 Annual Meeting of the American Neurological Association being held at The Baltimore Waterfront Marriott, October 12-14. The presentation, entitled, "A Phase 3 Trial of Firdapse(TM) Tablets in Lambert-Eaton Myasthenic Syndrome," to be delivered at the Neuromuscular Disease Special Interest Symposia, is scheduled for Sunday, October 12 at 5:20 pm (EDT). In addition, the Company will have a poster presentation (Poster #S737WIP) at the conference from 5:30 to 7:00 pm EDT. The presentation materials will be posted at www.catalystpharma.com in the Investors section under Events & Presentations.
CPRX: 2.90 (-0.02)
ITE, ESEA, CPRX Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Wed Oct 08, 3:34AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of SPDR Barclays Capital Intermediate Term Treas ETF (NYSE:ITE), Euroseas Ltd (NASDAQ:ESEA), Catalyst Pharmaceutical Partners Inc (NASDAQ:CPRX) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
ESEA: 0.77 (-0.01), CPRX: 2.90 (-0.02), ITE: 59.74 (+0.03)